The effects of a long term dihydroergotoxine treatment on agonist and antagonist striatal dopamine binding sites are dose and age related

Carlo Ferretti, Marinella Blengio, Carola Eva, Piera Ghi, Maria Carla Bosco, Paolo Portaleone

Research output: Contribution to journalArticle

Abstract

Chronic administration of dihydroergotoxine, at the two doses of 2.5 mg/kg and 5 mg/kg decreases the binding of dopamine 3H-agonists to striatal membranes. By contrast the binding of dopamine 3H-antagonists is decreased in the animals treated with the higher dose and increased in those treated with the lower one. In old rats, in which a partial loss of both 3H-antagonist and 3H-agonist binding sites is observed, the DHT treatment confirms to increase the binding of 3H-antagonists, without affecting that of 3H-agonists. Thus, aging and ergot alkaloids seem to discrimate between DA-agonist and DA-antagonist receptor sites suggesting that this receptors are separate entityes.

Original languageEnglish
Pages (from-to)967-978
Number of pages12
JournalPharmacological Research Communications
Volume18
Issue number10
DOIs
Publication statusPublished - 1986

Keywords

  • H-spiperone
  • HNPropyl-Norapomorphine
  • Aging brain
  • Dihydroergotoxine
  • Dopamine receptors
  • Ergot alkaloids

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The effects of a long term dihydroergotoxine treatment on agonist and antagonist striatal dopamine binding sites are dose and age related'. Together they form a unique fingerprint.

  • Cite this